This study is recruiting. It focuses on ADHD and currently lists participation information in Japan.
This study is looking at evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients for people with Attention-Deficit Hyperactivity Disorder. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to EB-1020 (Centanafadine) low dose, but direct benefit is not guaranteed.
The official record suggests in-person participation through a hospital, with sites including Hokkaido University Hospital in Sapporo. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis, while common reasons not to take part include pregnancy or breastfeeding and safety concerns that need urgent care first. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
This study may matter because it adds public evidence around adhd. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Japan.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company. Otsuka is a pharmaceutical company within the Otsuka group, with work across prescription medicines and healthcare products. The sponsor is based in Japan. Sponsor website: https://www.otsuka.co.jp/en/. You can verify the sponsor and study responsibility in the official registry record.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.